Welcome to our dedicated page for Callan JMB news (Ticker: CJMB), a resource for investors and traders seeking the latest updates and insights on Callan JMB stock.
Callan JMB Inc. (NASDAQ: CJMB) is an integrative logistics company focused on highly regulated, temperature‑sensitive supply chains for healthcare, pharmaceuticals, and emergency preparedness. This news page aggregates company‑specific announcements, business updates, and regulatory disclosures so readers can follow how Callan JMB’s logistics, cold chain, and monitoring capabilities evolve over time.
Recent news highlights include strategic agreements and growth initiatives that shape the company’s role in integrated freight and logistics. Callan JMB has reported a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech Inc., under which it will act as an independent third‑party overseer for manufacturing quality assurance, BARDA contract compliance, FDA audit readiness, federal reporting, and Strategic National Stockpile deployment coordination for Attune’s therapeutic pipeline. The company has also announced a strategic realignment toward cold‑chain infrastructure for GLP‑1 medications, including retrofitting its Texas cGMP facility for high‑capacity pharmaceutical‑grade refrigeration and positioning its cold‑chain technology for last‑mile fulfillment.
Other news items cover expansion into the food sampling sector, the launch of a subsidiary in India to establish a temperature‑controlled pharmaceutical warehouse, and upgrades to the proprietary Sentry Monitoring System to version 4.0, enabling web‑based access to temperature data and alarms from any device. Financial results releases provide context on revenue trends, contract extensions such as the long‑term City of Chicago emergency preparedness agreement, and capital markets activities including equity line arrangements.
Investors, analysts, and industry observers can use this page to review Callan JMB’s earnings releases, partnership announcements, technology upgrades, conference participation, and government contract updates, all in one place. Bookmark this feed to quickly access the latest CJMB news as reported in company press releases and SEC‑related communications.
Callan JMB (NASDAQ: CJMB) reported full‑year 2025 results and provided a business update on March 31, 2026. Revenue was $5.7M versus $6.6M in 2024; gross profit $2.1M and loss from operations $7.0M. Cash and cash equivalents were $2.1M.
The company highlighted new commercial agreements including a manufacturing oversight deal with Attune, a joint venture with Revival Health, expansion into India, renewed government contracts (Chicago and Oregon), vaccine lease programs, and an upgraded Sentry Monitoring System.
Callan JMB (NASDAQ: CJMB) announced independent infrastructure and oversight support for U.S. scale-up of the JKB-122 (Lodonal™) immune restoration platform on March 27, 2026.
Callan JMB will validate manufacturing, quality systems, and supply chain readiness to support Phase 2b/3 clinical advancement, U.S. GMP scale-up, and alignment with BARDA, DoD, and VA federal standards.
Callan JMB (NASDAQ: CJMB) will oversee manufacturing, quality assurance, and distribution governance for Attune Biotech's investigational drug lodonal™ (JKB-122) under IND 181314 for the treatment of Long COVID.
Services include CMO qualification, batch record review, supply chain verification, surge capacity assessment, and distribution pathway validation. Attune plans a randomized Phase 2b/3 trial; lodonal™ remains investigational and is protected by IP through 2041.
Callan JMB (NASDAQ:CJMB) announced that Founder, CEO and Chairman Wayne Williams will attend the 50th International GMP Conference on March 2-5, 2026 in Athens, Georgia.
The conference, co-sponsored by the University of Georgia College of Pharmacy and the FDA, focuses on pharmaceutical regulation, technology and supply-chain integrity.
Callan JMB (NASDAQ: CJMB) will participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10–11, 2026. The company will present virtually on March 10, 2026 at 10:30am ET. A webcast will be available at the provided link.
Investors can access the live webcast or contact iAccess Alpha or KCSA Strategic Communications for more information.
Callan JMB (NASDAQ:CJMB) will participate in the DealFlow Discovery Conference on January 28-29, 2026 at The Borgata, Atlantic City, NJ. The company is scheduled to present on Wednesday, January 28 at 3:00pm in Room #3. Callan JMB provides fulfillment, storage, monitoring, and cold chain logistics services for healthcare and emergency management agencies. For attendance or media queries, contact your DealFlow representative or email CallanJMB@kcsa.com.
Callan JMB (NASDAQ:CJMB) signed a strategic teaming agreement with Attune Biotech on Jan 15, 2026 to provide manufacturing oversight, federal deployment coordination, and commercialization support for Attune's multi-asset therapeutic pipeline. The parties expect approximately $50–$75 million in combined revenue over the next 5 years, with Callan JMB's share projected at about $25–$45 million depending on 50% or 60% profit-sharing by contract scope. Callan JMB cites validated surge-readiness capacity (a 500,000-unit simulation), 24-hour emergency deployment capability and Regional CONUS distribution within 48 hours, aiming to accelerate Attune's federal SNS integration and BARDA/DoD/VA procurement readiness.
Callan JMB (NASDAQ:CJMB) announced a strategic pivot into cold-chain infrastructure to serve GLP-1 pharmaceuticals, initiating phase-one retrofitting of its Texas cGMP facility to add high-capacity pharmaceutical refrigeration and host oral drug delivery equipment.
The company plans proprietary eco-friendly thermal shippers with real-time IoT sensors and 3PL software integration for telehealth home delivery. Management cites a projected $100 billion GLP-1 market by 2030 and highlights a recently extended $9.1 million government contract as financial support for the pivot.
Callan JMB (NASDAQ:CJMB) reported third-quarter results for the period ended September 30, 2025 and provided a business update. Q3 revenue was $1.4M and nine-month revenue was $4.6M. Gross profit was $0.5M for Q3 and $1.8M year-to-date. Operating loss was ($1.9M) in Q3 and ($4.5M) for nine months; cash totaled $2.8M at September 30, 2025.
Business developments include a $1.5M funding increase to extend the City of Chicago emergency-preparedness contract to June 2026 (total contract value $9.1M), formation of an India subsidiary with planned temperature-controlled pharmaceutical warehousing, a preliminary agreement to install oral drug delivery equipment at its Texas cGMP facility, expansion into food sampling, and an upgrade of its Sentry Monitoring System to v4.0 (HTML5).
Callan JMB (NASDAQ:CJMB) entered a preliminary agreement on November 13, 2025 to install an oral drug delivery manufacturer's production equipment at its cGMP facility in Spring Branch, Texas. The collaboration begins a phased effort to combine Callan JMB's cGMP warehousing, licensing, certification, and distribution capabilities with the client's manufacturing technology for fast-dissolving oral strips that offer an alternative to intravenous injections.
The companies are negotiating operational terms while Callan JMB positions this move as part of broader onshoring and manufacturing initiatives with global healthcare partners, including planned efforts with Revival Health.